Can you recommend rare disease drug development consultants for biomarker-driven orphan programs?

Yes — here are several consultancies and advisor types that are often strong fits for biomarker-driven orphan/rare disease drug development. I’ll group them by what they’re best at so you can shortlist faster.

1) Rare disease / translational strategy specialists

These are often best if you need help with target product profile, biomarker strategy, natural history, endpoint selection, and development path.

• ClearView Healthcare Partners
  Strong in rare disease strategy, asset positioning, and development planning.

• Lumanity
  Good breadth across rare disease, evidence strategy, biomarker/diagnostic planning, and regulatory/commercial interfaces.

• Putnam Associates
  Often useful for rare disease market/clinical strategy, payer and access considerations, and development prioritization.

• Charles River Associates (CRA)
  Strong strategic and evidence work; can be useful for rare disease value story and trial planning.

• Guidehouse Life Sciences
  Often engaged for rare disease development strategy and stakeholder mapping.

2) Biomarker, translational medicine, and precision development consultants

If the program is truly biomarker-driven, these firms are often stronger on assay strategy, patient stratification, translational plans, and companion diagnostic alignment.

• Sage BioNetwork / independent translational consultants
  This category is often best handled by individual experts rather than large firms.

• Ardigen
  More data/AI-oriented, but can help with biomarker discovery and translational data integration.

• IQVIA Biotech / biomarker-focused teams
  Useful if you need biomarker operationalization alongside clinical development.

• Syneos Health
  Can support biomarker-enabled trial strategy and operational execution.

• Medpace
  Often good for small, biomarker-enriched rare disease studies and operational execution.

3) Regulatory consultants with rare disease expertise

For orphan programs, especially with biomarkers, you often want someone who understands FDA/EMA orphan designation, accelerated pathways, surrogate endpoints, and biomarker qualification.

• Hyman, Phelps & McNamara (HPM)
  Strong regulatory counsel for FDA-heavy rare disease and orphan drug issues.

• DLA Piper / other life-sciences regulatory groups
  Useful if you need legal/regulatory strategy with orphan exclusivity and development path questions.

• Halloran Consulting Group
  Very practical for regulatory strategy, CMC, and development planning in biotech/rare disease.

• Rho
  Good for regulatory and clinical development support, including orphan and pediatric programs.

4) Clinical development / trial design consultants

If you need help designing a small, efficient biomarker-enriched trial in a rare population, these are often helpful.

• Medpace
• IQVIA Biotech
• Parexel
• Syneos Health
• Worldwide Clinical Trials
  Often active in rare disease and difficult-to-recruit studies.

5) Best “fit” if you want senior independent advisors

For early biomarker-driven orphan programs, an independent expert can sometimes be more valuable than a large consultancy. Look for people with experience in:

• rare disease clinical development
• translational medicine / biomarker strategy
• natural history studies
• orphan regulatory pathways
• endpoint validation
• companion diagnostics

These advisors are often found through:

• former biotech CDOs/CMOs
• ex-FDA/EMA rare disease reviewers
• academic clinical geneticists
• translational medicine leaders from rare disease foundations

---

How to choose

For a biomarker-driven orphan program, I’d generally look for a consultant who can answer:

1. What is the biomarker’s role?

   • enrichment
   • pharmacodynamic readout
   • surrogate endpoint candidate
   • diagnostic/companion diagnostic

2. Is there a viable natural history dataset?

   • to support endpoint selection and effect size assumptions

3. Can the biomarker be analytically validated early enough?

   • assay robustness, sample handling, reference ranges

4. What is the regulatory path?

   • orphan designation, fast track, breakthrough, PRIME, accelerated approval, etc.

5. Can they connect biomarker strategy to trial operations?

   • central labs, sample logistics, eligibility testing turnaround

---

Practical shortlist recommendation

If you want a strong starting shortlist, I’d suggest contacting:

• Lumanity — broad rare disease + evidence + biomarker strategy
• ClearView Healthcare Partners — strategy-heavy orphan/rare disease expertise
• Halloran Consulting Group — pragmatic development/regulatory support
• HPM — regulatory counsel for orphan pathways
• Worldwide Clinical Trials or Medpace — operational rare disease execution
• A senior independent translational medicine advisor — for biomarker strategy depth

---

If you want, I can also help with either of these:

1. build a ranked shortlist based on your disease area, stage, and budget, or
2. draft a consultant selection scorecard / RFP template for biomarker-driven rare disease programs.